Caitlin R Patten

Dr. Caitlin R Patten


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2017 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CPCaitlin R Patten
Caitlin R Patten
KWKendall Walsh
Kendall Walsh
TSTerry Sarantou
Terry Sarantou
LHLejla Hadzikadic‐Gusic
Lejla Hadzikadic‐Gusic
MFMeghan R. Forster
Meghan R. Forster
RWRichard L. White
Richard L. White

9 January 2020 in Health Expectations
Verified
Journal Article
Open access
PDF file
AYAlice Yan
Alice Yan
SMSandra Millon-Underwood
Sandra Millon-Underwood
AWAlonzo Walker
Alonzo Walker
CPCaitlin R Patten
Caitlin R Patten
DNDebra Nevels
Debra Nevels
MSMelinda Stolley
Melinda Stolley
Background: Patient‐centredness is considered an essential aspiration of a high‐quality health‐care system, and patient engagement is a critical precursor to patient‐centred care.Objectives: To engage patients, health‐care providers and stakeholders in identifying recommendations to address research and practice gaps that impact young African American breast cancer survivors.Methods: This paper reported an approach for research priority setting. This approach applies an engagement process (January‐September 2018) of using patient and stakeholder groups, patient storytelling workshops and a culminating storytelling conference in Wisconsin to generate relevant research topics and recommendations. Topics were prioritized using an iterative engagement process. Research priorities and recommendation were ranked over the conference by counting participants’ anonymous votes.Results: One hundred attendees (43 patients/family members, 20 providers/researchers and 37 community members) participated in the conference. Five topics were identified as priorities. The results showed that three priority areas received the most votes, specifically community outreach and education, providing affordable health care and engaging in complementary care practice. Stakeholders also agreed it is critical to ‘include youth in the conversation’ when planning for cancer support and educational programmes for caregivers, friends and family members.Conclusion: Storytelling as a patient engagement approach can build trust in the patient‐research partnership, ensure that patients are meaningfully engaged throughout the process and capture the diversity of patient experiences and perspectives.

1 October 2022 in The American Journal of Surgery
Verified
Journal Article
Closed access
PDF file
RHRana M. Higgins
Rana M. Higgins
KMKaren Marcdante
Karen Marcdante
KKKristina Kaljo
Kristina Kaljo
ESErin Strong
Erin Strong
CPCaitlin R Patten
Caitlin R Patten

19 July 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
PTPaige Teller
Paige Teller
TNToan T. Nguyen
Toan T. Nguyen
JTJennifer Tseng
Jennifer Tseng
LALisa Allen
Lisa Allen
CMCindy B. Matsen
Cindy B. Matsen
TSTerry Sarantou
Terry Sarantou

5 September 2022 in Journal of Surgical Research
Verified
Journal Article
Closed access
HHHannah Holland
Hannah Holland
AKAmanda Kong
Amanda Kong
EBErin Buchanan
Erin Buchanan
CPCaitlin R Patten
Caitlin R Patten

Verified
Journal Article
Open access
PDF file
JJJulie M Jorns
Julie M Jorns
YSYunguang Sun
Yunguang Sun
SMSailaja Kamaraju MD
Sailaja Kamaraju MD
YCYee Chung Cheng
Yee Chung Cheng
AKAmanda Kong
Amanda Kong
LCLubna Naaz Chaudhary
Lubna Naaz Chaudhary
PD-L1 immunohistochemistry (IHC) has become an established method for predicting cancer response to targeted anti-PD1 immunotherapies, including breast cancer (BC). The alternative PD-1 ligand, PD-L2, remains understudied but may be a complementary predictive marker. Prospective analysis of 32 breast cancers revealed divergent expression patterns of PD-L1 and PD-L2. PD-L1-positivity was higher in immune cells than in cancer cells (median = 5.0% vs. 0.0%; p = 0.001), whereas PD-L2-positivity was higher in cancer cells than immune cells (median = 30% vs. 5.0%; p = 0.001). Percent positivity of PD-L1 and PD-L2 were not correlated, neither in cancer cells nor immune cells. Based on a cut-point of ≥1% positivity, ER+ tumors (n = 23) were frequently PD-L2-positive (73.9%), whereas only 40.9% were PD-L1-positive. These data suggest differential control of cellular PD-L1 and PD-L2 expression in BC and a potential role for PD-L2 IHC as a complementary marker to PD-L1 to improve selection of aggressive ER+ BC that may benefit from anti-PD-1 therapy.